Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

By Silvio E. Inzucchi. Journal of the American Medical Association (JAMA), 2002

1,082 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. (2004, neutral): “Hypoglycemia 4 (3) 18 (14) 46 (36) 64 (25)”
Antidiabetic Potential of Medicinal Plants and Their Active Components (2019, background): “This mechanism works only in the presence of insulin [16,17].”
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise (2010, background): “Sulfonylureas, thiazolidinediones, and insulin are all associated with weight gain in patients with diabetes (6,7).”
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. (2005, neutral): “achieve glycemic treatment targets (8,9).”
Helping patients follow prescribed treatment: clinical applications. (2002, methodology): “This approach is insufficient compared with the guideline of making diet and exercise the foundation for diabetes control.(14,15) Rather, it follows the evidence from observational studies of nonadherence that show that the complexity and behavioral demand of the regimen are strong determinants of l”